Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure.
Twenty highly pretreated patients with HRPC received bevacizumab (10 mg/kg) and docetaxel (60 mg/m2) every 3 wk. All patients had bone metastases and eight had measurable lesions.
Eleven patients (55%) had major prostate-specific antigen (PSA) responses, and 3 (37.5%) had objective responses. Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. However, four major PSA responses were observed in patients previously nonresponsive to docetaxel alone. The treatment was well tolerated.
Our results show that the combination of bevacizumab and docetaxel is active and well tolerated. Continued investigation of bevacizumab with cytotoxic chemotherapy is warranted in HRPC.
Keywords: Bevacizumab, Chemotherapy, Docetaxel, Hormone-refractory prostate cancer.
a Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
b Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
c Rikshospital, Cancer Clinic, University of Oslo, Norway
d Clinica Urologica, Università degli Studi Federico II, Napoli, Italy
e Clinica Urologica, Seconda Università degli Studi, Naples, Italy
f U.O. Urologia, Istituto Nazionale Tumori, Fondazione “G. Pascale” IRCSS Napoli, Italy
g Oncology Section, Ospedali Riuniti, Bergamo, Italy
Corresponding author. Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy. Tel. +39 081 7463660; Fax: +39 081 8997370.
© 2008 European Association of Urology, Published by Elsevier B.V.